



March 3, 2020

NIPRO CORPORATION

Establishment of Dialysate Manufacturing Company in the U.S.

Nipro Corporation (“Nipro”) hereby announces that Nipro Medical Corporation, its consolidated subsidiary (Main office: Miami, Florida, the United States; Representative: Goichi Miyazumi, President), has taken over the dialysate manufacturing business of Dimesol USA LLC (“Dimesol”), a company that manufactures and markets dialysates in the United States, and has established a subsidiary that manufactures dialysates in Lewisberry, Pennsylvania, the United States as of December 13, 2019.

The U.S. population is around 330 million, of which around 0.5 million are dialysis patients, the largest number in the world. Therefore, a framework is required that enables us to seamlessly offer multiple services to customers, including the supply of high-quality dialysis products to meet patients’ needs and support for clinical training. To meet market needs, Nipro will expand its product lineup by adding dialysates to its existing disposable dialysis product lines, including dialyzers and blood circuits.

Overview of new company

- | | |
|-------------------------|---|
| (1) Company name: | Nipro Renal Solutions USA Corporation |
| (2) Representative: | Joseph Dawson, President |
| (3) Location: | Lewisberry, Pennsylvania, the United States |
| (4) Established: | December 13, 2019 |
| (5) Operations started: | January 2, 2020 |
| (6) Capital: | US\$8,900,000 |
| (7) Main business: | Manufacturing and sales of dialysates (liquid and powder) |

Summary of Dimesol

- | | |
|----------------------|---|
| (1) Company name: | Dimesol USA LLC |
| (2) Representatives: | Daniel Rangel, Stephen Callaghan |
| (3) Location: | Lewisberry, Pennsylvania, the United States |
| (4) Established: | October 17, 2016 |
| (5) Capital: | US\$200,000 |
| (6) Main business: | Manufacturing and sales of dialysates (liquid and powder) |